G100
- Generic Name
- G100
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Registration Number
- NCT03982121
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2020-09-09
- Target Recruit Count
- 52
- Registration Number
- NCT02501473
The Effects of GLA on Human Volunteers
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 32
- Registration Number
- NCT01397604
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath